ICU Medical Inc. is a leading medical device company that specializes in the development and manufacturing of innovative products for intravenous therapy, infusion systems, and related applications. The company focuses on enhancing patient safety and improving clinical outcomes through its advanced technologies, including smart infusion systems and closed-loop medication delivery solutions. With a commitment to quality and reliability, ICU Medical serves a wide range of healthcare settings, helping to streamline hospital operations and enhance the overall patient experience. Their extensive portfolio also encompasses vital components used in various healthcare environments, underscoring their role as a crucial player in the medical technology sector. Read More
ICU Medical (ICUI) Q3 2025 earnings crush estimates with EPS of $2.03, beating forecasts by 41.6%. The company also raised its full-year outlook, sparking a 10%+ stock surge.
Medical device company ICU Medical (NASDAQ:ICUI) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 8.9% year on year to $537 million. Its non-GAAP profit of $2.03 per share was 41.6% above analysts’ consensus estimates.
SAN CLEMENTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2025.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including ICU Medical (NASDAQ:ICUI) and its peers.
SAN CLEMENTE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2025 earnings release and conference call.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Shares of medical device company ICU Medical (NASDAQ:ICUI)
jumped 1.5% in the morning session after the company presented at the Wells Fargo 20th Annual Healthcare Conference, highlighting its strategic growth initiatives and robust performance.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, healthcare stocks were flat while the S&P 500 was up 11.6%.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
SAN CLEMENTE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September:
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Medical device company ICU Medical (NASDAQ:ICUI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 8.9% year on year to $543.6 million. Its GAAP profit of $1.43 per share was significantly above analysts’ consensus estimates.
Shares of medical device company ICU Medical (NASDAQ:ICUI)
fell 10.5% in the morning session after the company reported second-quarter results where a significant earnings beat was overshadowed by a year-over-year revenue decline and concerning cash flow performance. The medical device company reported a GAAP profit of $1.43 per share, significantly reversing a loss from the prior year and handily beating analyst expectations. However, investors appeared to focus on the 8% year-over-year decline in revenue, which landed at $548.9 million, even though it slightly surpassed analyst forecasts. Furthermore, the company's free cash flow was a negative $8.49 million, a stark reversal from a positive $62.67 million in the same period last year, indicating pressure on its cash generation. Despite the company also issuing full-year profit guidance that was well ahead of Wall Street estimates, the revenue dip and negative cash flow seemingly weighed more heavily on investor sentiment.
